Today's Information

Provided by: LUMOSA THERAPEUTICS CO., LTD.
SEQ_NO 1 Date of announcement 2022/08/09 Time of announcement 15:20:47
Subject 
 LUMOSA Board of Directors approved the
consolidated financial report for the second quarter of
2022
Date of events 2022/08/09 To which item it meets paragraph 31
Statement 
1.Date of the board of directors submitted or approved:2022/08/09
2.Date of the audit committee approved:2022/08/09
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):7,705
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):2,486
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(160,369)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(379,645)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(379,645)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(379,645)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(2.34)
11.Total assets end of the period (thousand NTD):1,952,547
12.Total liabilities end of the period
(thousand NTD):210,731
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,741,816
14.Any other matters that need to be specified:NA

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Lumosa Therapeutics Co. Ltd. published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 09:05:03 UTC.